[ASBMR 2009 Report. Meeting report on the ASBMR. ASBMR topics].
This overview summarizes topics from the 31(th) Annual Meeting of ASBMR held at Colorado Convention Center in Denver on September 11-15, 2009. Out of the 300 orally presented papers, I picked up mainly translational and clinical studies, focusing on hormones such as PTH, vitamin D, estrogen and FGF23, and new anti-osteoporotic drugs.
Inoue
Daisuke
D
Third Department of Medicine, Teikyo University Chiba Medical Center, Japan.
D048868:Adaptor Proteins, Signal Transducing; D000818:Animals; D050071:Bone Density Conservation Agents; D019485:Bone Morphogenetic Proteins; D004967:Estrogens; D000089703:Fibroblast Growth Factor-23; D005346:Fibroblast Growth Factors; D005819:Genetic Markers; D006023:Glycoproteins; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy / Q000209:etiology; D010281:Parathyroid Hormone; D014807:Vitamin D
D048868:Adaptor Proteins, Signal Transducing; D050071:Bone Density Conservation Agents; D019485:Bone Morphogenetic Proteins; D004967:Estrogens; C000717427:FGF23 protein, human; C000717428:Fgf23 protein, mouse; D005819:Genetic Markers; D006023:Glycoproteins; D036341:Intercellular Signaling Peptides and Proteins; D010281:Parathyroid Hormone; C486030:Sost protein, mouse; D014807:Vitamin D; D005346:Fibroblast Growth Factors; D000089703:Fibroblast Growth Factor-23